{"id":11739,"date":"2021-02-09T17:40:20","date_gmt":"2021-02-09T12:10:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11739"},"modified":"2021-07-24T12:58:16","modified_gmt":"2021-07-24T07:28:16","slug":"latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","title":{"rendered":"Deerfield\/ Dana-Farber\u2019s USD 130 Million Cancer Research Deal; FDA-Approval to BMS\u2019 Breyanzi &#038; TG Therapeutics\u2019 Ukoniq; EU Marketing Rights for ViiV Healthcare\u2019s Rukobia"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a2d406cf1d07\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a2d406cf1d07\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\/#Deerfield_and_Dana-Farber_Establish_Links_in_USD_130_Million_Cancer_Research_Deal\" >Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\/#Breyanzi_BMS_Blood_Cancer_CAR-T_Therapy_Receives_FDA_Nod\" >Breyanzi, BMS\u2019 Blood Cancer CAR-T Therapy Receives FDA Nod<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\/#TG_Therapeutics_Wins_FDA_Nod_for_Ukoniq_for_Marginal_Zone_Lymphoma_and_Follicular_Lymphoma\" >TG Therapeutics Wins FDA Nod for Ukoniq for Marginal Zone Lymphoma and Follicular Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\/#European_Marketing_Authorisation_to_ViiV_Healthcares_Rukobia_for_Multidrug-resistant_HIV\" >European Marketing Authorisation to ViiV Healthcare\u2019s Rukobia for Multidrug-resistant HIV<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Deerfield_and_Dana-Farber_Establish_Links_in_USD_130_Million_Cancer_Research_Deal\"><\/span><strong>Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. The move came not long after healthcare investor giant Deerfield Management has forged a partnership to create the Center for Protein Degradation, investing worth USD 80 million.<\/p>\n\n\n\n<p>In the pharmaceutical and healthcare domain, where discoveries take ample time, and success rates are unpredictable, translational research helps in ensuring better and innovative discoveries that act as the fuel for revolutionizing breakthroughs in the domain.&nbsp;<\/p>\n\n\n\n<p>For the same reason, Deerfield has decided to invest USD 130 Million over the next ten years at Dana-Farber. The funding will help to create and launch Riverway Discoveries. Through Riverway, Deerfield plans to fund selected projects and provide operational support. The committee will constitute members from Dana-Farber and Deerfield to consider proposals from Dana-Farber researchers later this month.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Breyanzi_BMS_Blood_Cancer_CAR-T_Therapy_Receives_FDA_Nod\"><\/span><strong>Breyanzi, BMS\u2019 Blood Cancer CAR-T Therapy Receives FDA Nod<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb\u2019s (BMS) CAR T-cell therapy <strong>Breyanzi<\/strong>, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\"><strong>Diffuse large B-cell lymphoma (DLBCL).<\/strong><\/a><\/p>\n\n\n\n<p>Breyanzi targets CD19, a protein that is highly expressed on the surface of B cells, which remain there following the transformation of these cells from normal to malignant. As per the company, their one-time CAR-T cell therapy will be crucial in clinical practice in relapsed or refractory large B-cell lymphoma cases.&nbsp;<\/p>\n\n\n\n<p>Breyanzi will come with a price tag of USD 410,300 wholesale price, said the company, justifying it after taking into consideration several factors including<em> medical and clinical value, patient value, and societal value.<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TG_Therapeutics_Wins_FDA_Nod_for_Ukoniq_for_Marginal_Zone_Lymphoma_and_Follicular_Lymphoma\"><\/span><strong>TG Therapeutics Wins FDA Nod<\/strong> <strong>for Ukoniq for Marginal Zone Lymphoma<\/strong> <strong>and Follicular Lymphoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>About time that the PI3K cancer drug portfolio has another member along with Gilead\u2019s Zydelig, Verastem Oncology\u2019s Copiktra, and Bayer\u2019s Aliqopa. TG Therapeutics has announced the U.S. FDA Ukoniq (umbralisib) for the treatment of adult patients with relapsed or refractory<a href=\"https:\/\/www.delveinsight.com\/report-store\/marginal-zone-lymphoma-market?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\"> <strong>marginal zone lymphoma<\/strong><\/a> (MZL) who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/follicular-lymphoma-market-insights?utm_source=blog&amp;utm_medium=news&amp;utm_campaign=v\"><strong>follicular lymphoma<\/strong><\/a> (FL) who have received at least three prior lines of systemic therapy.<\/p>\n\n\n\n<p>What makes it interesting to note is Ukoniq is the first and only, oral, once-daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon, and maybe this is what makes it costlier than the others.&nbsp;<\/p>\n\n\n\n<p>Ukoniq\u2019s approval was backed by Phase 2 <strong>UNITY-NHL<\/strong> Trial (NCT02793583). The drug received priority review for the MZL. Furthermore, it was also granted Breakthrough Therapy Designation (BTD) for the treatment of MZL and orphan drug designation (ODD) for the treatment of MZL and FL.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"European_Marketing_Authorisation_to_ViiV_Healthcares_Rukobia_for_Multidrug-resistant_HIV\"><\/span><strong>European Marketing Authorisation to ViiV Healthcare\u2019s Rukobia for Multidrug-resistant HIV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A lot has been achieved in the HIV treatment market sphere. Earlier, the life expectancy of a person with HIV was only one-two years from the time of diagnosis, however, the collaboration of the pharma companies and the scientific community have made strides of improvement in the domain. Today, the domain has effective combination ART regimens that help HIV patients have a near-normal life expectancy.<\/p>\n\n\n\n<p>Recently, the European Union blessed ViiV Healthcare\u2019s Rukobia for the treatment of patients with HIV that have developed resistance to other antiretroviral therapy (ART). The nod came a few months after the CHMP opinionated positively for the same.&nbsp;<\/p>\n\n\n\n<p>Rukobia&nbsp; is the first-in-class HIV attachment inhibitor. It has been recommended as an add-on therapy to other ARTs in adults who can not be given any other suppressive antiviral regimen. The therapy scored the FDA-approval last year in the same domain acting as hope for the small subset of people with multi-drug resistant HIV at the risk of disease progression.&nbsp;&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Deerfield and Dana-Farber Establish Links in USD 130 Million Cancer Research Deal&nbsp; Deerfield Management has entered into a research agreement with Dana-Farber Cancer Institute to fuel the development of therapeutics and diagnostics for cancer. The move came not long after healthcare investor giant Deerfield Management has forged a partnership to create the Center for Protein [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11740,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18763,2150,17305],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-11739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-breyanzi","tag-deerfield","tag-tg-therapeutics","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Deerfield\/ Dana-Farber\u2019s Deal; FDA-Nod to BMS\u2019 Breyanzi &amp; TG\u2019 Ukoniq<\/title>\n<meta name=\"description\" content=\"Deerfield\/ Dana-Farber\u2019s USD 130 M Deal; FDA-Approval to BMS\u2019 Breyanzi &amp; TG Therapeutics\u2019 Ukoniq; ViiV Healthcare\u2019s Rukobiain EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Deerfield\/ Dana-Farber\u2019s Deal; FDA-Nod to BMS\u2019 Breyanzi &amp; TG\u2019 Ukoniq\" \/>\n<meta property=\"og:description\" content=\"Deerfield\/ Dana-Farber\u2019s USD 130 M Deal; FDA-Approval to BMS\u2019 Breyanzi &amp; TG Therapeutics\u2019 Ukoniq; ViiV Healthcare\u2019s Rukobiain EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-09T12:10:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:28:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Deerfield\/ Dana-Farber\u2019s Deal; FDA-Nod to BMS\u2019 Breyanzi & TG\u2019 Ukoniq","description":"Deerfield\/ Dana-Farber\u2019s USD 130 M Deal; FDA-Approval to BMS\u2019 Breyanzi & TG Therapeutics\u2019 Ukoniq; ViiV Healthcare\u2019s Rukobiain EU","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","og_locale":"en_US","og_type":"article","og_title":"Deerfield\/ Dana-Farber\u2019s Deal; FDA-Nod to BMS\u2019 Breyanzi & TG\u2019 Ukoniq","og_description":"Deerfield\/ Dana-Farber\u2019s USD 130 M Deal; FDA-Approval to BMS\u2019 Breyanzi & TG Therapeutics\u2019 Ukoniq; ViiV Healthcare\u2019s Rukobiain EU","og_url":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-02-09T12:10:20+00:00","article_modified_time":"2021-07-24T07:28:16+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","url":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield","name":"Deerfield\/ Dana-Farber\u2019s Deal; FDA-Nod to BMS\u2019 Breyanzi & TG\u2019 Ukoniq","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq.jpg","datePublished":"2021-02-09T12:10:20+00:00","dateModified":"2021-07-24T07:28:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Deerfield\/ Dana-Farber\u2019s USD 130 M Deal; FDA-Approval to BMS\u2019 Breyanzi & TG Therapeutics\u2019 Ukoniq; ViiV Healthcare\u2019s Rukobiain EU","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-tg-therapeutics-viiv-bms-deerfield#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq.jpg","width":772,"height":482,"caption":"Deerfield Dana Farber Deal FDA Nod to BMS Breyanzi & TG Ukoniq"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/02\/09173527\/Deerfield-Dana-Farber-Deal-FDA-Nod-to-BMS-Breyanzi-TG-Ukoniq-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Breyanzi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Deerfield<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">TG Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breyanzi<\/span>","<span class=\"advgb-post-tax-term\">Deerfield<\/span>","<span class=\"advgb-post-tax-term\">TG Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 9, 2021","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 9, 2021 5:40 pm","modified":"Updated on Jul 24, 2021 12:58 pm"},"featured_img_caption":"Deerfield Dana Farber Deal FDA Nod to BMS Breyanzi & TG Ukoniq","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11739"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11740"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11739"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11739"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}